Edaravone/Taurine

依达拉奉/牛磺酸

Report date: 2023/12/08 10:55:00

Base Information

Drug NameEdaravone/Taurine
Drug Alias Name复方依达拉奉注射液
ClassificationSmall molecules
Mechanisms of ActionFree radicals scavengers
TargetsFree radicals
Therapy Area/IndicationsAmyotrophic Lateral SclerosisBrain InfarctionNervous System Diseases
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsYes EdaravoneTaurine
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesNanjing Yoko Biomedical Co LtdSouth China Center For Innovative Pharmaceuticals
China Registration ClassN/A

Develop Information

Active CompaniesNanjing Yoko Biomedical Co LtdSouth China Center For Innovative PharmaceuticalsNanjing Yoko Pharmaceutical Co Ltd +[4] 
Inactive CompaniesN/A
Active IndicationsAmyotrophic Lateral SclerosisBrain Infarction
Inactive IndicationsNervous System Diseases

Other Information

ATC CodeN/A
Related LinksN/A